This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-16. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Diethyltryptamine (DET), also known as N,N-diethyltryptamine or T-9, is a psychedelic drug of the tryptamine family closely related to dimethyltryptamine (DMT). It is taken orally, but can also be used by parenteral routes. The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor among others. It has not been found to occur endogenously. DET is a close structural homologue of DMT and dipropyltryptamine (DPT). Other analogues of DET include 4-HO-DET (ethocin), ethocybin (4-PO-DET), and 5-MeO-DET. DET was first synthesized in 1956 by Stephen Szára and subsequently described in material published in 1957. More systematic studies were reported later by Szára and colleagues and independently by Böszörményi and colleagues.
== Settlement == The Judge Donald W. VanArtsdalen of United States District Court ruled that the three had contributed significantly to the Government's case against SmithKline. ordered the government to pay $42.3 million to three men who helped the Justice Department expose Medicare fraud at SmithKline Beecham Clinical Laboratories Inc. The Justice Department had resisted paying the men the 15 to 25 percent share of SmithKline's settlement specified for whistleblowers by the federal False Claims Act. The department argued that most of the $325 million settlement was obtained through its nationwide Labscam investigations that had nothing to do with the men, Robert J. Merena, Charles W. Robinson, Jr., and Glenn Grossenbacher. But U.S. District Judge Donald W. VanArtsdalen ruled Wednesday that they made a major contribution to the government's case and that they helped bring in nearly all of the settlement.
== Separations == Chemical separation techniques are frequently utilized in nuclear forensics as a method of reducing the interferences and to facilitate the measurement of low level radionuclides. Purification that occurs rapidly as progeny in-growth begins immediately following purification is ideal.
In large cities, it is difficult to transmit power by overhead cables, so underground cables are used. But underground cables get heated and the resistance of the wire increases, leading to waste of power. Superconductors could be used to increase power throughput, although they would require cryogenic liquids such as nitrogen or helium to cool special alloy-containing cables to increase power transmission. Several feasibility studies have been performed and the field is the subject of an agreement within the International Energy Agency.
The National Safety Council calculated that the lifetime odds of dying from an opioid overdose (1 in 96) in 2017 were greater than the lifetime odds of dying in an automobile accident (1 in 103) in the United States. The opioid epidemic, combined with the Patient Protection and Affordable Care Act, has led to a situation called the Florida shuffle, where a drug user moves between drug rehabilitation centers so those centers may bill the user's insurance company. In one study, a decision analytical model of the US population aged 12 years or older found that "under the status quo, an estimated 484,429 individuals were projected to die of fatal opioid overdose" between 2020 and 2029. However, a combination of "reducing opioid prescribing, increasing naloxone distribution, and expanding treatment for opioid use disorder was associated with an estimated 179,151 lives saved when compared to the status quo." Healthcare professionals are also among those heavily affected by this epidemic. Studies have been done to determine how well nursing students, nurses, and even doctors are prepared to treat patients affected by opioid addictions. The studies have pointed to the fact that nurses and other healthcare professionals are highly undertrained in this area. As a result, many specific education programs have been proposed and implemented into nursing education institutions.
Sources: en.wikipedia.org
=== Biological properties === Chitosan is biodegradable and biocompatible. Chitosan enhances the transport of polar drugs across epithelial surfaces. The enhanced chitosan uptake is mainly due to the interaction of positively charged chitosan with cell membranes, activation of chlorine–bicarbonate exchange channels, and reorganization of proteins associated with epithelial tight junctions, thus opening epithelial tight junctions. However, it is not approved by the FDA for drug delivery. Purified quantities of chitosan are available for biomedical applications. Chitosan inhibits the growth of different bacteria and fungi by mechanisms involving several factors, including the degree of deacetylation, pH, divalent cations, and solvent type.
== Structure == In bacteria, HDH is a single chain polypeptide; in fungi it is the C-terminal domain of a multifunctional enzyme which catalyses three different steps of histidine biosynthesis; and in plants it is expressed as a nuclear encoded protein precursor which is exported to the chloroplast.
Glycoproteins have differential levels of glycosylations and adsorb SDS more unevenly at the glycosylations, resulting in broader and blurred bands. Membrane proteins, because of their transmembrane domain, are often composed of the more hydrophobic amino acids, have lower solubility in aqueous solutions, tend to bind lipids, and tend to precipitate in aqueous solutions due to hydrophobic effects when sufficient amounts of detergent are not present. This precipitation manifests itself for membrane proteins in a SDS-PAGE in "tailing" above the band of the transmembrane protein. In this case, more SDS can be used (by using more or more concentrated sample buffer) and the amount of protein in the sample application can be reduced. An overloading of the gel with a soluble protein creates a semicircular band of this protein (e. g. in the marker lane of the image at 66 kDa), allowing other proteins with similar molecular weights to be covered. A low contrast (as in the marker lane of the image) between bands within a lane indicates either the presence of many proteins (low purity) or, if using purified proteins and a low contrast occurs only below one band, it indicates a proteolytic degradation of the protein, which first causes degradation bands, and after further degradation produces a homogeneous color ("smear") below a band. The documentation of the banding pattern is usually done by photographing or scanning. For a subsequent recovery of the molecules in individual bands, a gel extraction can be performed.
== Herbal == Eryngium planum is used in European folk medicine as a diuretic, a stimulant, and an appetizer owing to its essential oils, and bioactive compounds, and in this usage it may be known as Eryngii plani herba or Eryngii plani radix.
Keuning S, Janssen DB, Witholt B (1985). "Purification and characterization of hydrolytic haloalkane dehalogenase from Xanthobacter autotrophicus GJ10". J. Bacteriol. 163 (2): 635–9. doi:10.1128/JB.163.2.635-639.1985. PMC 219169. PMID 4019411. Scholtz R, Leisinger T, Suter F, Cook AM (1987). "Characterization of 1-chlorohexane halidohydrolase, a dehalogenase of wide substrate range from an Arthrobacter sp". J. Bacteriol. 169 (11): 5016–21. doi:10.1128/jb.169.11.5016-5021.1987. PMC 213902. PMID 3667524. Yokota T, Omori T, Kodama T (1987). "Purification and properties of haloalkane dehalogenase from Corynebacterium sp. strain m15-3". J. Bacteriol. 169 (9): 4049–54. doi:10.1128/jb.169.9.4049-4054.1987. PMC 213707. PMID 3624201. Poelarends GJ, van Hylckama Vlieg JE, Marchesi JR, Freitas Dos Santos LM, Janssen DB (1999). "Degradation of 1,2-dibromoethane by Mycobacterium sp. strain GP1". J. Bacteriol. 181 (7): 2050–8. doi:10.1128/JB.181.7.2050-2058.1999. PMC 93616. PMID 10094681. Poelarends GJ, Wilkens M, Larkin MJ, van Elsas JD, Janssen DB (1999). "Degradation of 1,3-dichloropropene by pseudomonas cichorii 170". Appl. Environ. Microbiol. 64 (8): 2931–6. doi:10.1128/AEM.64.8.2931-2936.1998. PMC 106795. PMID 9687453. Nagata Y, Miyauchi K, Damborsky J, Manova K, Ansorgova A, Takagi M (1997). "Purification and characterization of a haloalkane dehalogenase of a new substrate class from a gamma-hexachlorocyclohexane-degrading bacterium, Sphingomonas paucimobilis UT26". Appl. Environ. Microbiol. 63 (9): 3707–10. Bibcode:1997ApEnM..63.3707N. doi:10.1128/AEM.63.9.3707-3710.1997.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.